Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenetic Biosciences (XBIO) Common Equity (2023 - 2025)

Xenetic Biosciences (XBIO) has disclosed Common Equity for 5 consecutive years, with $4.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 43.78% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Sep 2025, down 43.78%, and an annual FY2024 reading of $6.0 million, down 38.67% over the prior year.
  • Common Equity was $4.0 million for Q3 2025 at Xenetic Biosciences, down from $4.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $12.9 million in Q1 2023 and bottomed at $4.0 million in Q3 2025.
  • Average Common Equity over 3 years is $8.0 million, with a median of $7.4 million recorded in 2024.
  • The sharpest move saw Common Equity crashed 32.52% in 2024, then tumbled 43.78% in 2025.
  • Year by year, Common Equity stood at $9.8 million in 2023, then plummeted by 38.67% to $6.0 million in 2024, then plummeted by 34.14% to $4.0 million in 2025.
  • Business Quant data shows Common Equity for XBIO at $4.0 million in Q3 2025, $4.5 million in Q2 2025, and $5.1 million in Q1 2025.